Kornimate/medical-research-clean huggingface dataset:
outcomes for patients with gastro-esophageal reflux disease

Conditions: Gastro-esophageal Reflux Disease

Summary: gastro-esophageal reflux disease (gerd), the most common cause of erosive esophagitis (ee), remains highly prevalent worldwide. gerd poses substantial burden on both patients and society. ee treatment patterns and unmet needs have been well-studied overseas, but evidence gaps still exist in china. to fill these evidence gaps, real-world evidence for gerd and ee are needed. to understand gerd market we will analysis :patient profile,gerd patient journey within hospital (first present, get diagnosed, receive initial and maintenance treatment),medication cost,department differentiation. to investigate current treatment patterns of gerd / ee in china we will analysis: current agents used and treatment duration in clinical practice treatment patterns by different reimbursement status treatment pattern by ee/nerd. to get healing rate of ee we will analysis: real-world efficacy of the current standard treatment (i.e. ppis) for patient with two test results of gastroscopy. the data required for this project are accessible in hospital electronic system; no specific data collection tools or methods are required for this project design. only algorithms for retrieving and extracting eligible patients' records are required and will be developed by hlt based on the eligibility criteria defined in this protocol.


Eligibility criteria:
inclusion criteria: * medical records of gerd, nerd and/or ee diagnoses （icd code scope will be confirmed later）from january 1st, 2015 to december 31st, 2017. ogerd is typically characterized by symptoms of heartburn and acid regurgitation. a diagnosis of ee or nerd can only be confirmed upon endoscopic examination. * all ages, males or females * a primary diagnosis of gerd/nerd/ee for treatment patterns, patients are also required to have received one episode of treatment during the analysis period. for rw treatment efficacy, the population will be restricted to the ee treatment population who underwent at least two endoscopy examinations. exclusion criteria: - no exclusion criteria will be applied for investigating diagnosis since all patients diagnosed with gerd, nerd, or ee should be captured regardless of whether they have medical conditions that affect their treatments. a patient will not be eligible for investigating treatment patterns and rw treatment efficacy if he/she has any of the following exclusion criterion: * a post-operative diagnosis of gastrointestinal cancers * a diagnosis of esophageal foreign bodies or neoplasms * a history of gastric or esophageal surgery * zollinger-ellison syndrome * primary esophageal motility disorders (ex: achalasia) * esophageal strictures * eosinophilic esophagitis * identified as pregnant or lactating * hospitalized (inpatient) patients (to be confirmed by expert.) due to gerd as primary or secondary diagnosis
m-ptcy vs bucy in haploidentical hsct for acute leukemia

Conditions: Acute Leukemia

Summary: this study intends to evaluate the efficiency and safety of m-ptcy as conditioning regimen in haploidentical hsct for acute leukemia, so as to provide a new conditioning regimen for allogeneic hematopoietic cell transplantation.

haploidentical related donor transplantation is now considered an important alternative to allogeneic hematopoietic stem cell transplantation (allo-hsct). posttransplant cyclophosphamide (ptcy) has revolutionized haplo hct with acceptable rates of engraftment, graft-versus-host disease (gvhd), relapse, and survival.to prolonger pfs, os and alleviate gvhd, we combined mitoxantrone liposomes with ptcy as conditioning regimen in allogeneic hematopoietic cell transplantation.

Eligibility criteria:
inclusion criteria: 1. the patients meet the diagnostic criteria for acute leukemia(except apl). 2. expecting life span is more than 3 months. 3. the patients intended allogeneic hematopoietic stem cell transplantation. exclusion criteria: 1. previously received doxorubicin or other anthracycline therapy, the total cumulative dose of doxorubicin≥360 mg/m2. 2. cardiac function and disease meet one of the following conditions: 1. long qtc syndrome or qtc intervalgt≥480 ms; 2. complete left bundle branch block, grade ii or iii degree atrioventricular block; 3. severe, uncontrolled arrhythmia requiring drug treatment; 4. new york society of cardiology class ≥ ii; 5. cardiac ejection fraction (lvef) lower than 50% or lower than the study the lower limit of the central laboratory test value range; 6. history of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, clinically serious pericardial disease history within 6 months before recruitment, or ecg evidence of acute ischemia or active conduction system abnormalities. 3. alanine aminotransferase (ast) and aspartate aminotransferase (alt) \> 2.5 times the upper limit of normal (uln); total bilirubin \> 1.5 times upper limit of normal; serum creatinine \> 1.5 times the upper limit of normal. 4. suffering from other malignant tumors in the past or at the same time ; 5. exclude patients with severe active infection or other underlying diseases who cannot tolerate chemotherapy; 6. human immunodeficiency virus (hiv) infected patients (hiv antibody positive); 7. active hepatitis b and c infection； 8. pregnant women, lactating women, and patients who refuse to take effective contraceptive measures during the study; 9. severe mental disorders who do not cooperate with treatment; 10. judgment by the investigator , there are patients who are not suitable to participate in this study.
basic and clinical studies of levodopa/carbidopa/entacapone in the treatment of early parkinson's disease

Conditions: Parkinson Disease

Summary: this is a, open-label, single-arm 8-week investigation of levodopa/carbidopa/entacapone in the treatment of early parkinson's disease.

this study will enroll subjects who have a diagnosis of pd with hoehn-yahr stage 1.5-3.0 and assess the impact of low dosage of levodopa/carbidopa/entacapone treatment on the motor function and quality of life among pd patients.

Eligibility criteria:
inclusion criteria: * male or female and greater from 30 to 80. * diagnosis of idiopathic pd according to the mds pd diagnostic criteria (2015). * hoehn-yahr stage of 1.5-3.0 ("open" stage). * not on anti-pd medication or stable on anti-pd medication for at least 30 days. exclusion criteria: * diagnosis of atypical parkinsonian syndrome, vascular parkinsonism or drug-induced parkinsonism. * history of surgery within 6 months. * alcoholism, drug abuse, or severe cognitive impairment (including severe alzheimer's disease) * psychiatric illness, epilepsy, pregnancy and breastfeeding, and clinically significant concomitant illnesses * participation in another clinical trial within 2 months. * with dyskinesia. * any other condition that, in the opinion of the investigator, makes them ineligible for enrolment.

Keywords: parkinson disease levodopa/carbidopa/entacapone
assessment of 99mtc-ntp 15-5 uptake on cartilage, a new proteoglycan tracer

Conditions: Osteoarthritis, Knee; Breast Cancer

Summary: this study is a phase i clinical trial aimed to determine the recommended dose of 99mtc-ntp 15-5 to obtain the best tracer joints contrast on images without any toxicity.


Eligibility criteria:
inclusion criteria: inclusion criteria specific to group 1: - patient with painful unilateral osteoarthritis of the knee as femorotibial pattern defined by a radiographic score of 0/1 from kellgren / lawrence and an average womac score\> or equal to 4 and by minor disorders at mri (mocart 2.0 score\> 70). inclusion criteria specific to group 2: * patient with non-metastatic breast cancer, hormone receptor positive, her2 negative, with indication for adjuvant therapy with aromatase inhibitor; treatment not yet started. * age \<60 years common inclusion criteria: * patient with at least 31 healthy joints (based on clinical assessment) * signed written informed consent. * affiliation to a health insurance scheme. * for women of childbearing age : negative serum pregnancy test at inclusion (less than 7 days prior injection of 99mtc-ntp 15-5). * willing and able to comply with study visits, treatment, exams and the protocol. exclusion criteria: * patients \<18 years of age. * pregnant or lactating patient. * bmi\> 30 * history of known allergy to excipients contained in the solution of 99mtc-ntp 15-5 * chronic inflammatory rheumatism (rheumatoid arthritis, spondyloarthropathy, psoriatic arthritis, etc.) diffuse arthritis (at least 3 joints affected), autoimmune connectivitis, fibromyalgia. * known chronic joint pathology: osteoarthritis affecting at least 3 joints, autoimmune disease, inflammatory rheumatism (except unilateral knee arthritis). * persons deprived of their liberty, under guardianship / curatorship, or safeguard of justice. * treatment with nsaids or cessation of less than 48 h. * inability to comply with medical requirement / follow-up of the trial for geographic, family, social or psychological reasons. these conditions should be discussed with the patient before registration in the study.

Keywords: cartilage proteoglycan tracer
double-blind and placebo-controlled study on intervention effect of medium and long chain fatty acid triglyceride on glycolipid homeostasis in patients with metabolic syndrome and mechanisms

Conditions: Metabolic Syndrome

Summary: double-blind and placebo-controlled study on intervention effect of medium and long chain fatty acid triglyceride on glycolipid homeostasis in patients with metabolic syndrome and mechanisms


Eligibility criteria:
inclusion criteria: * diagnosed metabolic syndrome according to idf diagnostic criteria; * rarely eating out of home; * aged between 40 and 70 years. exclusion criteria: * breastfeeding or pregnancy; * history of heart disease, coronary heart disease, stroke, cerebral infarction, viral liver disease (hepatitis a, hepatitis b, etc.), chronic kidney disease (gfr\<60 ml/min) or cancer; * diabetic ketoacidosis or hyperketosis; * drug use has changed in the past six months; * taking insulin; * used mlct edible oil in the past six months; * have participated in other clinical trials in the last three months.

Keywords: metabolic syndrome mlct
integration of a trained language model to improve glycemic control through increased physical activity: a fully digital my heart counts smartphone app randomized trial

Conditions: Type2diabetes

Summary: type 2 diabetes (t2d) is one of the most common and fastest growing diseases, affecting 1 in 8 adults (nearly 800 million) worldwide by 2045. sedentary behavior and increased adiposity are major risk factors for t2d. cardiovascular disease is the leading cause of death in those with t2d, while diabetic microvascular disease, causing kidney disease, neuropathy, and retinopathy, contributes to t2d morbidity. physical activity is one of the most potent therapies in preventing/treating t2d and its complications. mean daily steps is a proxy for physical activity, with even modest improvements in step count (i.e., +500 steps) associated with decreased t2d and mortality. however, adherence to regular physical activity remains low in t2d patients, with short-term decreases in daily step count associated with impaired glycemic control and t2d recurrence. the investigators have developed an artificial intelligence (ai) language model (similar to chatgpt), which can automatically generate coaching prompts to encourage physical activity by incorporating an individual's stage of change. the investigators will extend our research using the my heart counts (mhc) smartphone app to 1) validate the efficacy of the ai-generated prompts in patients with t2d and 2) perform a longer-term randomized crossover trial using the language model as a social accountability chatbot - encouraging participants to maintain their physical activity changes over months. the investigators hypothesize that my ai-assisted coaching prompts will significantly increase 1) mean daily step count by 500 steps in 1,000 adults recruited nationwide over a 7-day period, and 2) improve hba1c and weight via long-term behavior change over a 24-week intervention period.


Eligibility criteria:
inclusion criteria: * individuals aged ≥18 years old, with a clinical diagnosis of t2d, able to read and understand english, and who are physically able to walk, will be included in our study exclusion criteria: * criteria that fall outside of the inclusion criteria.
proposal for parental guidance and early stimulation in children with congenital heart disease: randomized trial

Conditions: Congenital Heart Disease

Summary: problem: with the increased survival rate of children with congenital heart disease, other health problems, in addition to the clinic, have emerged, such as the risks of developmental delay to which these children are exposed. there is a need for low-cost intervention studies that seek to minimize these risks. objective: to evaluate the effect of an early stimulation program using parents as vectors of intervention, on the neurodevelopment of children with chd methodology: randomized clinical trial, conducted with 44 dyads of parents-babies with ch considered as medium and high risk for developmental delays according to the guidelines of the american heart association (2012). the study will consist of two groups g1 (intervention) and g2 (controls). g1 parents will receive guidance for 6 weeks of stimulation activities and will be instructed to keep an online execution diary, direct with the researcher through videos, and messages via cell phone. g2 parents will receive the standard guidelines currently used in pediatric cardiology clinics. children from both groups will be assessed at the beginning and end of the 6 weeks by the bayley baby and toddler development scales (3rd edition). a questionnaire on the applicability of the protocol will be administered to the parents of the intervention group expected results: better neuropsychomotor performance in children after applying the early stimulation protocol. perspectives: create a body of information that can serve as a basis for the formulation of policies for intervention and surveillance of the development of this population.


Eligibility criteria:
inclusion criteria: for babies * diagnosis of congenital heart disease up to 3 months old. * stable clinical condition (with medical clearance to receive the intervention), for parents * parents are literate * acceptance of the responsible to participate in the research. * have a mobile device capable of sending and receiving messages and videos. exclusion criteria: for babies * suspected or diagnosed genetic syndrome; * musculoskeletal or neurological malformation associated * inability to establish a primary caregiver as in the case of baby under state supervision. for parents * illiteracy * presence of deafness, blindness or physical disability, when another family member cannot be responsible for the application of the protocol.

Keywords: congenital heart disease children developmental parents training
a study of photobiomodulation (pbm) therapy in people with oral graft-versus-host disease (gvhd) after stem cell transplant

Conditions: Graft-Versus-Host Disease; GVHD; Undefined

Summary: the purpose of this study is to find out whether photobiomodulation/pbm therapy using the thor lx2.3 therapy system is a safe and effective treatment for oral graft-versus-host disease/gvhd.


Eligibility criteria:
inclusion criteria: * allo-hct recipients * age ≥ 4 years-old * oral cgvhd with nih-modified omrs score ≥ 3 who have failed ≥ 1 line of therapy, including topical corticosteroids.. * no change in systemic immunosuppressive therapy (type or intensity level) within 2 weeks prior to enrollment. * if a patient is currently using another oral topical treatment for mouth lesions/symptoms, patient must be stable on this treatment for ≥2 weeks prior to study enrollment. patient may continue same topical dose/frequency during the study period. exclusion criteria: * presence of an active uncontrolled infection. subjects with a controlled infection receiving definitive therapy for 48 hours prior to enrollment are eligible. * personal history of mucosal head and neck cancer in the past 5 years. * pregnant or breastfeeding. * the subject or guardian is unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests. * any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.

Keywords: graft-versus-host disease gvhd chronic graft versus host disease oral photobiomodulation memorial sloan kettering cancer center 22-271
resistance on antithrombotic drugs in ischemic heart disease

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to determine whether aspirin and clopidogrel resistance measured with multiplate function analyser has a good correlation with incidence of major adverse cardiac events in patients with coronary artery disease (cad).

our plan is to enroll 180 patients with diagnosed cad who electively undergo percutaneous coronary intervention (pci). blood samples will be taken just before the procedure and one day after the procedure and analysed on multiplate function analyser. assessing aspirin and clopidogrel resistance incidence using multiplate platelet function analyzer we will also try to find resistance correlation with the incidence of major adverse cardiac events in a one year follow up.

Eligibility criteria:
inclusion criteria: * elective pci * \> 7 days on aspirin 100mg therapy before the intervention * \> 7 days on clopidogrel 75mg therapy before the intervention exclusion criteria: * loading dose of clopidogrel * \< 7 days on aspirin therapy before the intervention * myocardial infarction less than 30 days before the intervention * cerebrovascular incident less that three months before the intervention * haemorrhagic diathesis * trc \< 100 * htc \< 30% * creatinine \> 140

Keywords: aspirin resistance coronary artery disease clopidogrel resistance major adverse cardiac events multiplate platelet function analyser percutaneous coronary intervention
safety study of outdoor and indoor mobility in people with spinal cord injury (robotics spinal cord injury ekso).

Conditions: Spinal Cord Injury

Summary: the aim of this study will be to evaluate the safety and the efficacy of a new robotic exoskeleton device in subjects with spinal cord injury (sci) and in subjects with other neurological disease with an impairment of lower limbs.

in this study, 30 participants with chronic spinal cord injury will undergo a 8-week training schedule for ambulation with the ekso™ device. ekso™ is a wearable bionic suit which enables individuals with any amount of lower extremity weakness to stand up and walk over ground with a natural, full weight bearing, reciprocal gait. walking is achieved by the user's weight shifts to activate sensors in the device which initiate steps. battery-powered motors drive the legs, replacing deficient neuromuscular function. ekso provides functional based rehabilitation, over ground gait training, and upright, weight bearing exercise unlike any other. it has been designed for the needs of busy therapists treating a wide range of patients in a single day. the suit is strapped over the users´ clothing with easy adjustments to transition between patients in as little as five minutes. before, during and after training sessions the subjects will perform standardised assessments and complete questionnaires to assess the functional and psychological effects of the exoskeleton.

Eligibility criteria:
inclusion criteria: * chronic motor complete or incomplete cervical and thoracic (c7-t12) spinal cord injury. * skin integrity. * adequate hip, knee and ankle range of motion. * spasticity level of 3 or less (ashworth scale). exclusion criteria: * cardiological or respiratory comorbidity. * hemodynamic instability. * presence of unhealed fractures. * presence of heterotopic ossification that may impede walking. * presence of osteoporosis.

Keywords: robot spinal cord injury gait quality of life rehabilitation lower limb
psychological and clinical outcomes of splint therapy with and without doctor-patient communication in tmd management

Conditions: Temporomandibular Disorders (TMDs)

Summary: this study aimed to evaluate the psychological and clinical outcomes of patients undergoing splint therapy with or without enhanced doctor-patient communication in the management of temporomandibular disorders (tmds). the study compared treatment approaches to determine their impact on patient satisfaction and clinical results.

temporomandibular disorders (tmds) are prevalent conditions characterized by jaw pain, functional limitations, and psychological distress. this study investigated the impact of splint therapy combined with enhanced doctor-patient communication on psychological well-being and clinical outcomes. participants were randomly assigned to receive standard splint therapy or splint therapy with additional doctor-patient communication strategies. the primary outcomes include clinical and psychological status improvements, measured over six months, and patient satisfaction, assessed over a one-year period. the results aimed to provide insights into optimizing treatment strategies for tmd patients.

Eligibility criteria:
inclusion criteria: * patients complaining of pain in the orofacial region (either arthrogenous and/or myogenous tmd) in the last 3 months, who never underwent any type of treatment for tmd's. * age ≥16 years. exclusion criteria: * patients who have already undergone any treatment for tmd's, edentulous patients, * patients with any systemic disease that could cause joint and/or muscle changes, * patients who were undergoing drug treatment for the condition, current pregnancy, or breastfeeding.

Keywords: splint therapy doctor-patient communication non-surgical tmd treatment tmds management
improving patient experience: bmba

Conditions: Bone Marrow Cancer; Leukemia; Lymphoma; Multiple Myeloma; Hematologic Cancer

Summary: this study seeks to determine if patients undergoing a bone marrow biopsy/aspiration (bmba) procedure who receive distraction techniques have lower levels of distress and pain, and higher post-procedure satisfaction, compared to those receiving standard-of-care. intervention 1 is guided meditation in a virtual reality (vr) headset. intervention 2 is comprised of environmental changes to the room (via nature-themed decals) and music.

this study seeks to determine if patients undergoing a bone marrow biopsy/aspiration (bmba) procedure who receive distraction techniques have lower levels of distress and pain, and higher post-procedure satisfaction, compared to those receiving standard-of-care. intervention 1 is guided meditation in a virtual reality (vr) headset. intervention 2 is comprised of environmental changes to the room (via nature-themed decals) and music.

Eligibility criteria:
inclusion criteria: * provide signed and dated informed consent form * willing to comply with all study procedures * over 18 years of age * prior history of at least 1 (one) bmba at jefferson outpatient oncology office within the past 2 (two) years * visiting the jefferson outpatient oncology office for a bmba procedure during the study duration exclusion criteria: * inability to read questions in english * inability to answer questions autonomously * history of vertigo * legal blindness in both eyes * severe or profound hearing loss, or deafness